Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Izastobart (TJ210001) in Advanced Solid Tumors
NCT04947033Phase 1Recruiting
- Sponsor
- I-Mab
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of izastobart in solid tumor, sponsored by I-Mab. Primary endpoints: Rate and Severity of Dose-limiting toxicity at 28 days and Maximum Tolerated Dose at 21 days. Started Dec 2023; status: recruiting.
02
Drugs
izastobart
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04947033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04947033.